Dongoyaro

Dongoyaro contains limonoids (azadirachtin, nimbolide, gedunin) and polyphenols (quercetin, rutin at 4150.625 µg/g, catechin at 315.404 µg/g) that modulate NF-κB and MAPK inflammatory pathways, scavenge free radicals, and disrupt microbial and parasitic cell function. In vitro studies demonstrate leaf extract inhibits SARS-CoV-2 replication with an IC50 of 8.541 µg/mL and a selectivity index of 52.8, exceeding the threshold recommended for drug advancement, though no human clinical trials have yet confirmed these effects.

Origin & History

Azadirachta indica is native to the Indian subcontinent but has been widely naturalized across sub-Saharan Africa, Southeast Asia, and tropical regions worldwide, thriving in semi-arid to tropical climates with well-drained soils and high heat tolerance. In West Africa, particularly Nigeria, it is called 'Dongoyaro' (meaning 'tall boy' in Hausa, referencing its height) and grows abundantly as a roadside and village tree. The tree is drought-resistant, grows at altitudes up to 700 meters, and is cultivated both for shade and as a medicinal resource, with leaves, bark, seeds, and oil all harvested for traditional use.

Historical & Cultural Context

Azadirachta indica has been used therapeutically for over 4,000 years in Ayurvedic medicine, where it is called 'Nimba' and described in classical Sanskrit texts such as the Charaka Samhita as a bitter tonic for purifying blood, treating skin disorders, and managing febrile illness. Introduced to West Africa during historical trade and migration routes, the tree became deeply integrated into Yoruba and Hausa healing traditions in Nigeria under the name 'Dongoyaro,' where it is one of the most frequently cited plants in ethnobotanical surveys of antimalarial herbs. Traditional healers prepare leaf decoctions, bark teas, and seed oil preparations for conditions ranging from malaria and typhoid fever to skin infections, oral hygiene (chewing sticks), and gastrointestinal complaints, reflecting a comprehensive pharmacopoeia built on centuries of empirical observation. The United Nations has recognized neem's global traditional importance, and in Nigeria it remains an accessible, low-cost botanical medicine particularly in rural communities with limited access to pharmaceutical antimalarials.

Health Benefits

- **Antimalarial Activity**: Limonoids including gedunin and nimbolide interfere with Plasmodium falciparum development by disrupting heme detoxification and parasite protein synthesis, providing a mechanistic basis for the centuries-old Yoruba and Hausa use of leaf decoctions to manage malaria fever.
- **Antiviral Potential**: Ethanolic leaf extract inhibits SARS-CoV-2 replication in Vero E6 cell models at an IC50 of 8.451–8.541 µg/mL, with a cytotoxic concentration (CC50) of 446.2 µg/mL, yielding a selectivity index of 52.8 that surpasses the >50 benchmark for lead compound advancement.
- **Antibacterial Action**: Limonoids and polyphenols exhibit minimum inhibitory concentrations of 25–100 µg/mL against both Gram-positive and Gram-negative bacterial strains within 30 minutes of exposure, disrupting bacterial cell wall integrity and membrane function.
- **Anti-inflammatory Effects**: Nimbolide and azadirachtin suppress proinflammatory cytokines TNF-α and IL-6 by downregulating NF-κB and MAPK signaling cascades, reducing systemic inflammation associated with infections, skin conditions, and metabolic disease.
- **Antioxidant Protection**: High rutin content (4150.625 µg/g) alongside quercetin and catechin scavenges reactive oxygen species, upregulates endogenous antioxidant enzymes (superoxide dismutase, catalase), and inhibits lipid peroxidation as demonstrated in multiple in vitro assays.
- **Immunomodulatory Support**: Bioactive limonoids elevate CD4+ and CD8+ T-lymphocyte populations and modulate innate immune responses, suggesting potential utility in supporting host defense against chronic or recurrent infections.
- **Wound Healing and Skin Health**: Tannins and terpenoids in leaf and bark preparations promote tissue regeneration, inhibit secondary bacterial infection at wound sites, and reduce dermal inflammation, consistent with traditional topical application of leaf pastes across West Africa.

How It Works

Azadirachtin and nimbolide inhibit NF-κB nuclear translocation, reducing transcription of proinflammatory cytokine genes (TNF-α, IL-1β, IL-6) and suppressing COX-2-mediated prostaglandin synthesis, while simultaneously activating MAPK-dependent anti-apoptotic pathways in host cells under oxidative stress. Polyphenolic constituents—particularly quercetin and rutin—donate hydrogen atoms to neutralize superoxide and hydroxyl radicals, chelate transition metals that catalyze Fenton reactions, and directly upregulate Nrf2-ARE pathway expression, increasing intracellular glutathione and superoxide dismutase activity. Gedunin and related limonoids disrupt Plasmodium falciparum heat shock protein 90 (PfHsp90) function, impairing parasite protein folding and survival within erythrocytes, which underpins the antimalarial ethnopharmacological claim. Antimicrobial activity occurs through membrane depolarization in bacterial cells and competitive inhibition of viral replication enzymes, as evidenced by the low IC50 values recorded against SARS-CoV-2 in cell-based assays.

Scientific Research

The body of evidence for Dongoyaro (Azadirachta indica) consists predominantly of in vitro cell-culture studies and animal model experiments, with no peer-reviewed randomized controlled trials (RCTs) in human populations identified in the current literature. In vitro antiviral research using Vero E6 cells demonstrated a SARS-CoV-2 IC50 of 8.541 µg/mL and a selectivity index of 52.8, results that are statistically robust at the cellular level but cannot be directly extrapolated to human dosing or clinical outcomes. Antibacterial studies report MIC values of 25–100 µg/mL against common pathogens, and phytochemical profiling via HPLC has reliably quantified key compounds such as rutin (4150.625 µg/g) and catechin (315.404 µg/g) in leaf extracts. The overall evidence base is preclinical in nature; while mechanistically compelling, the absence of Phase I/II human trials means efficacy and optimal dosing for any therapeutic indication remain scientifically unvalidated.

Clinical Summary

No completed human RCTs for Dongoyaro (Azadirachta indica) are documented in accessible peer-reviewed literature, making it impossible to report effect sizes, confidence intervals, or number-needed-to-treat figures from clinical populations. Preclinical antiviral data (IC50 8.541 µg/mL, SI 52.8 vs. SARS-CoV-2) and antimalarial mechanistic data involving PfHsp90 disruption represent the strongest experimental evidence available, both generated in controlled laboratory settings. Traditional ethnopharmacological use across Nigerian Yoruba and Hausa communities—where leaf decoctions are consumed for febrile illness including malaria—provides observational support but lacks the methodological rigor to establish causality or dose-response relationships. Confidence in therapeutic claims remains low to moderate from an evidence-based medicine standpoint; clinical translation is a research priority given the strength of preclinical signals.

Nutritional Profile

Neem leaves contain significant polyphenol concentrations including rutin (4150.625 µg/g), catechin (315.404 µg/g), vanillic acid (151.947 µg/g), chlorogenic acid (99.167 µg/g), protocatechuic acid (59.866 µg/g), and quercetin (38.274 µg/g) as quantified by HPLC in ethanolic extracts. Limonoid terpenoids—azadirachtin, nimbin, nimbolide, gedunin, nimbidin, and salannin—are the dominant therapeutically active compounds, concentrated especially in seeds and oil fractions, though precise mg/g concentrations vary substantially by plant part, geographic origin, and extraction solvent. Secondary metabolites include β-sitosterol, ascorbic acid, n-hexacosanol, saponins (highest in aqueous extracts), tannins, alkaloids, steroids, and glycosides. Bioavailability of limonoids and polyphenols is poorly characterized in humans; lipophilic compounds like azadirachtin likely benefit from oil-based or emulsified formulations, while water-soluble polyphenols are partially absorbed from aqueous decoctions.

Preparation & Dosage

- **Leaf Decoction (Traditional)**: Boil 10–20 g of fresh or dried leaves in 500 mL water for 15–20 minutes, strain, and consume 1–2 cups daily; this is the most common Yoruba and Hausa preparation for fever and malaria management, though dose is not clinically validated.
- **Dried Leaf Powder**: Traditional use suggests approximately 1–2 g per day in divided doses; no standardized pharmaceutical dose established from RCTs.
- **Ethanolic/Methanolic Extract**: Used in research and nutraceutical formulations; effective concentrations in vitro range from 8–100 µg/mL depending on target organism, but human equivalent doses have not been established.
- **Neem Oil (Seed Cold-Press)**: Applied topically for skin conditions or consumed in very small amounts (historically 5–10 mL/day) for internal use; oral consumption of undiluted oil carries toxicity risk and is not recommended without medical supervision.
- **Standardized Supplements**: Commercial neem capsules often standardized to 0.3–2% azadirachtin or total limonoid content; typical label doses range from 300–500 mg extract twice daily, but clinical evidence for these doses is absent.
- **Timing Notes**: Leaf decoctions traditionally taken on an empty stomach in the morning for antimalarial use; topical paste applied twice daily to affected skin areas.

Synergy & Pairings

Dongoyaro leaf extract is traditionally combined with Moringa oleifera and Vernonia amygdalina (bitter leaf) in Nigerian herbal formulations targeting malaria and febrile infections, with each plant contributing complementary antimalarial limonoids, antioxidant flavonoids, and anti-inflammatory sesquiterpenes that may act additively on Plasmodium falciparum and host inflammatory pathways. In Ayurvedic contexts, neem is paired with turmeric (Curcuma longa) to enhance anti-inflammatory outcomes, as curcumin and nimbolide both suppress NF-κB through distinct binding interactions, potentially producing additive inhibition of TNF-α and IL-6 production. Neem polyphenols may also synergize with black pepper (Bioperine/piperine), which inhibits P-glycoprotein efflux transporters and CYP3A4 metabolism, potentially improving bioavailability of otherwise poorly absorbed limonoids.

Safety & Interactions

Short-term use of leaf extracts at conventional traditional doses is generally considered low-risk based on cytotoxicity data (CC50 >350–446 µg/mL in cell models, SI >50), but systematic human safety studies are absent, and adverse event rates in population use are not formally documented. Neem oil taken orally in doses above 5–10 mL has been associated with toxic encephalopathy and Reye's-like syndrome in children in case reports, and oral neem oil is contraindicated in infants and young children. Potential drug interactions include attenuation of immunosuppressant therapies (cyclosporine, tacrolimus) due to immunomodulatory upregulation of T-cell populations, and theoretical potentiation of antidiabetic drugs given hypoglycemic activity reported in animal studies. Neem preparations are traditionally contraindicated in pregnancy due to reported uterotonic and abortifacient properties inferred from animal studies and ethnopharmacological accounts; use during lactation is likewise not established as safe, and pregnant or breastfeeding individuals should avoid therapeutic doses.